Abstracts tagged "Fatigue"

Abstract Number: 0315 • ACR Convergence 2021
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Samantha Wratten¹, Natasha Griffiths², Carl Cooper², Jessica Flynn², Rebecca Hall³, Linda Abetz-Webb², Wolfgang Hueber⁴, Briana Ndife⁵ and Pushpendra Goswami⁴, ¹Adelphi Values, Macclesfield, United Kingdom, ²Adelphi Values, Bollington, United Kingdom, ³Adelphi Values Ltd, Bollington, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis, East Hanover, NJ
Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…
Abstract Number: 0462 • ACR Convergence 2021
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Eva-Maria Bachmair¹, Kathryn Martin Remmes¹, Lorna Aucott¹, Emma Dures², Richard Emsley³, Stuart Gray⁴, Elizabeth Kidd⁵, Vinod Kumar⁶, Karina Lovell⁷, Graeme MacLennan¹, Paul McNamee¹, John Norrie⁸, Lorna Paul⁹, Jon Packham¹⁰, Stuart Ralston¹¹, Stefan Siebert⁴, Alison Wearden⁷, Gary Macfarlane¹² and Neil Basu⁴, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of West of England, Bristol, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶NHS Tayside, Dundee, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, ⁸Usher Institute – University of Edinburgh, Edinburgh, United Kingdom, ⁹Glasgow Caledonian University, Glasgow, Scotland, United Kingdom, ¹⁰Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom, ¹¹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ¹²Epidemiology Group, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
Background/Purpose: Inflammatory rheumatic disease (IRD) related fatigue is pervasive and disabling, even in otherwise stable disease. Although cognitive-behavioural approaches (CBAs) and personalised exercise programmes (PEP)…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0717 • ACR Convergence 2021
Association of Fatigue with Disease Activity in Myositis
Tissa Bijoy George¹, Anjana Chandrasekhara Pillai², Siamak Moghadam-Kia³, Nicole Neiman⁴, Dana Ascherman³, Chester Oddis³, Dianxu Ren⁴ and Rohit Aggarwal³, ¹UPMC McKeesport, Monroeville, PA, ²UPMC, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The Idiopathic inflammatory myopathies are a heterogeneous group of rare systemic autoimmune diseases with muscle as the primary target. Fatigue is one of the…
Abstract Number: 0246 • ACR Convergence 2020
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fatigue is commonly described in chronic illnesses, especially in auto-immune disorders such as systemic lupus erythematosus (SLE). We aim to study the prevalence of…
Abstract Number: 1727 • ACR Convergence 2020
Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
Samantha Rodriguez-Muguruza¹, Bernard Combe², Oliver Valero³, Francis Guillemin⁴, Alejandro Olivé-Marqués⁵, Bruno Fautrel⁶, Ramon Fontova¹ and Cédric Lukas⁷, ¹Joan XXIII Hospital, Tarragona, Spain, ²University of Montpellier, Montpellier, France, ³Department of Statistics, Autonoma de Barcelona University, Barcelona, Spain, ⁴Universite de Lorraine CIC INSERM, Nancy, France, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: to determine and characterize fatigue trajectories over 10 years of follow-up in a cohort of early RA patients. Methods: We selected patients fulfilling the 2010…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 1735 • ACR Convergence 2020
Effect of Aerobic Land-based Exercise Intervention on Fatigue in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Samar Aboulenain¹, Arezo Farhangi², Elie Donath¹ and Ozlem Pala³, ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Palm Beach Gardens, FL, ³University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Persistent fatigue can be debilitating for patients with rheumatoid arthritis (RA). Although fatigue partially improves after the initiation of DMARDs, suggesting an inflammatory process,…
Abstract Number: 0276 • ACR Convergence 2020
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Raeann Whitney¹, Amanda Eudy², Cynthia Coffman³, Megan Clowse⁴, Lisa Criscione-Schreiber⁵, Jayanth Doss², Rebecca Sadun², Kai Sun² and Jennifer Rogers⁶, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke, Durham, NC
Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…
Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Samar Aboulenain¹, Elie Donath¹ and Ozlem Pala², ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 1838 • ACR Convergence 2020
Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)
Marquis Chapman¹, Sarthak Gupta¹, Jun Chu¹, Mohammad Naqi¹, Zerai Manna², Mir Ali Mazhar¹, Adam Munday¹, Marybeth Stockman¹, Anam Ahmad¹, Gayle McCrossin¹, Bart Drinkard¹, Lisa Chin¹, Mariana Kaplan³, Randall Keyser¹, Leighton Chan¹ and Sarfaraz Hasni², ¹National Institutes of Health, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease of female predominance. One of the most debilitating symptoms experienced by SLE-patients is persistent…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Hope Rainey¹, Kristy Bell¹, Violeta Rus², Daniel Wallace³, Claire Dykas¹, Mary Mora¹, Maggy Comberg¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA, ²University of Maryland School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center/UCLA, Los Angeles, CA
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].